RespireRx Pharmaceuticals Inc. (RSPI) financial statements (2021 and earlier)

Company profile

Business Address 126 VALLEY ROAD
GLEN ROCK, NJ 07452
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 000000
Cash and cash equivalents 000000
Prepaid expense 000000
Deferred costs     0 
Other undisclosed current assets  000 0
Total current assets: 000000
Noncurrent Assets
Property, plant and equipment   (0)000
Prepaid expense  00000
Other undisclosed noncurrent assets   0   
Total noncurrent assets:  00000
TOTAL ASSETS: 000000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 433212
Employee-related liabilities 210210
Interest and dividends payable     00
Other undisclosed accounts payable and accrued liabilities 222112
Debt 100000
Due to related parties 111111
Other undisclosed current liabilities 221210
Total current liabilities: 765633
Noncurrent Liabilities
Total liabilities: 765633
Temporary equity, carrying amount    0  
Stockholders' equity
Stockholders' equity attributable to parent, including: (7)(6)(4)(5)(3)(2)
Preferred stock 000   
Common stock 000000
Additional paid in capital 159159157152145139
Accumulated deficit (167)(164)(162)(158)(148)(142)
Other undisclosed stockholders' equity attributable to parent    001
Total stockholders' equity: (7)(6)(4)(5)(3)(2)
Other undisclosed liabilities and equity    (0)  
TOTAL LIABILITIES AND EQUITY: 000000

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues
(Revenue, Net)
     00
Cost of revenue
(Financial Services Costs)
      (0)
Gross profit:     00
Operating expenses (2)(2)(4)(8)(5)(4)
Other undisclosed operating income      0
Operating loss: (2)(2)(4)(8)(5)(4)
Nonoperating income (expense)
(Foreign Currency Transaction Gain (Loss), before Tax)
 0(0)    
Interest and debt expense (0)(0)(0)(1)(1)(0)
Net loss: (2)(2)(4)(9)(6)(4)
Other undisclosed net income (loss) attributable to parent  (0)0(0)02
Net loss attributable to parent: (2)(3)(4)(9)(6)(3)
Preferred stock dividends and other adjustments    (0)(0)(0)
Other undisclosed net loss available to common stockholders, basic      (10)
Net loss available to common stockholders, diluted: (2)(3)(4)(9)(6)(13)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (2)(2)(4)(9)(6)(4)
Comprehensive loss, net of tax, attributable to parent: (2)(2)(4)(9)(6)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: